Labs / Assays & in vitro testing

Phaim
London, United Kingdom · phaim.co.uk
On your own
Free. Their own form.
Through Midgard
Midgard sends your request to the lab and keeps the order's messages, papers and payments in one place. Free to ask. 1% platform fee if you keep the order on Midgard.
Phaim is a London-based biotechnology company developing antigen-specific immunotherapies for autoimmune disease. Its first application is Type 1 Diabetes, and its pipeline also includes psoriasis, rheumatoid arthritis, and multiple sclerosis.
Their website has a general contact form; we send your quote request through it.
What they offer
Antigenic Immune Modulation (AIM) platform development
Develops a therapeutic platform designed to cure, improve, halt, or prevent autoimmune disease by resetting immune tolerance.
Type 1 diabetes drug candidate development
Develops DMX4001 as the first application of its platform for Type 1 Diabetes.
Preclinical study design and validation
Has completed preclinical animal work and validated CMC processes to support scale-up for clinical studies.
Autoimmune biomarker development
Maintains proprietary biomarkers to characterize type 1 diabetes risk and likely disease progression.
What they work on
- Modalities
- Small molecule, Antibody, ADC, Peptide
- Species and models
- animal study, pancreas, Antigen Presenting Cells, regulatory T cells
- Assays and studies
- CMC process validation
- Therapeutic areas
- Type 1 Diabetes, psoriasis, rheumatoid arthritis, multiple sclerosis, autoimmune disease
- Sites
- London, United Kingdom
- Founded
- 2019
Similar labs. Sai Life, Aurigene Pharmaceutical Services, Esco Aster, Porton
Found in a contract services directory. Listing built from phaim.co.uk. Work here? Claim this listing.